Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease.
Saved in:
| Title: | Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease. |
|---|---|
| Authors: | Bradshaw, Daniel1 (AUTHOR) daniel.bradshaw@ukhsa.gov.uk, Abramowicz, Iga2 (AUTHOR), Bremner, Stephen2,3 (AUTHOR), Verma, Sumita3 (AUTHOR), Gilleece, Yvonne1 (AUTHOR), Kirk, Sarah1 (AUTHOR), Nelson, Mark4 (AUTHOR), Housman, Rosalie4 (AUTHOR), Miras, Helena5 (AUTHOR), Orkin, Chloe5 (AUTHOR), Fox, Ashini6 (AUTHOR), Curnock, Michael6 (AUTHOR), Jennings, Louise7 (AUTHOR), Gompels, Mark7 (AUTHOR), Clarke, Emily8 (AUTHOR), Robinson, Rachel8 (AUTHOR), Lambert, Pauline9 (AUTHOR), Chadwick, David9 (AUTHOR), Perry, Nicky2 (AUTHOR) |
| Source: | PLoS ONE. 7/14/2023, Vol. 18 Issue 7, p1-16. 16p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
